IMDELLTRA Receives FDA Approval as the First T-Cell Engager Therapy for Advanced Small Cell Lung Cancer
Amgen has reported that the FDA has approved IMDELLTRA™ (tarlatamab-dlle) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following platinum-based chemotherapy. This accelerated approval is based on promising response rates and duration of response observed in clinical trials. Ongoing approval for this use may depend on confirming and detailing the clinical benefits in further confirmatory trials.
"The FDA's approval of IMDELLTRA represents a significant milestone for patients fighting...
